Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States

References

• Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004
   Google Scholar
• Stoops WW, Hatton KW, Lofwall MR, et al. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl) 2010;212:193-203
   PubMed Web of Science ®Google Scholar
• Ling W, Mooney L, Hillhouse M. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev 2011;30:300-5
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55-70
   PubMed Web of Science ®Google Scholar
• Gilson AM, Kreis PG. The burden of the nonmedical use of prescription opioid analgesics. Pain Med 2009;10(Suppl 2):S89-100
   PubMed Web of Science ®Google Scholar
• Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 2005;20:1082-6
   PubMed Web of Science ®Google Scholar
• Jan SA. Patient perspective, complexities, and challenges in managed care. J Manag Care Pharm 2010;16(1 Suppl B):S22-5
   Google Scholar
• Veilleux JC, Colvin PJ, Anderson J, et al. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010;30:155-66
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11:469-79
   PubMedGoogle Scholar
• United Nations Office on Drugs and Crime (UNODS), 2012. World Drug Report 2012. United Nations publication, Sales No. E.12.XI.1. http://www.un.org/en/hq/dpi/od.shtml
   Google Scholar
• Centers for Disease Control and Prevention. Home and recreational safety: unintentional poisoning. Atlanta, GA: CDC, last updated 2 July 2013. Available at: http://www.cdc.gov/HomeandRecreationalSafety/Poisoning/index.html [Last accessed 27 June 2013]
   Google Scholar
• Results from the 2009 National Survey on Drug Use and Health: Volume 1. Summary of National Findings. Available at: http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9Results.htm [Last accessed 10 November 2011]
   Google Scholar
• Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011;305:1346-7
   PubMed Web of Science ®Google Scholar
• Bruneau J, Roy E, Arruda N, et al. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012;107:1318-27
   PubMed Web of Science ®Google Scholar
• Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm 2010;16(1 Suppl B):S14-21
   PubMed Web of Science ®Google Scholar
• Chandwani HS, Strassels SA, Rascati KL, et al. Estimates of charges associated with emergency department and hospital inpatient care for opioid abuse-related events. J Pain Palliat Care Pharmacother 2013;27:206-13
   PubMedGoogle Scholar
• Clark HW. Office-based practice and opioid-use disorders. N Engl J Med 2003;349:928-30
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Banner W, Bradt P, et al. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatrics 2013;163:1377-83
   PubMed Web of Science ®Google Scholar
• Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat 2014;47:27-34
   PubMed Web of Science ®Google Scholar
• Kharitonova E, Aballéa S, Clay E, et al. Analysis of persistence and healthcare costs in the US Medicaid population opioid-dependent patients treated with buprenorphine/naloxone film and tablet formulations. ISPOR 18th Annual International Conference, New Orleans, 18–22 May 2013
   Google Scholar
• Clay E, Khemiri A, Zah V, et al. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence. J Med Econ 2014;17:626-36
   Google Scholar
• Kharitonova E, Clay E, Ruby J, et al. Retrospective study of persistence and healthcare costs in the US opioid-dependent Medicaid population treated with buprenorphine/naloxone film and tablet formulations. ISPOR 18th Annual International Conference, New Orleans, 18–22 May 2013
   Google Scholar
• Degenhardt L, Larney S, Randall D, et al. Causes of death in a cohort treated for opioid dependence between 1985 and 2005. Addiction 2014;109:90-9
   PubMed Web of Science ®Google Scholar
• Office of the Legislative Counsel, Patient Protection and Affordable Care Act, (“PPACA”; Public Law 111-148) 2010
   Google Scholar
• Truven Health Analytics. Medicaid Expansion: Profiling the Future Medicaid-Eligible Population. Truven Health Analytics, 2012
   Google Scholar
• U.S. Department of health and human services, Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4856Findings). Rockville, MD. 2010
   Google Scholar
• Clay E, Khemiri A, Ruby J, et al. Patient persistence with buprenorphine/naloxone film and tablet formulations in the treatment of opioid dependence in the United States: results from a 2010–2012 privately insured retrospective database. 15th International Society of Addiction Medicine Conference, Kuala Lumpur, 21–23 November 2013
   Google Scholar
• Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care 2011;17(Suppl 8):S235-48
   Google Scholar
• Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009;104(6):982-92
   Google Scholar